Company

SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics develops therapies for rare oncology conditions, with a focus on precision oncology.

About

Founded in 2017 in Stamford, US, SpringWorks Therapeutics is a biopharmaceutical company developing treatments for rare oncology conditions. Its pipeline includes nirogacestat and mirdametinib, the latter studied for NF1 plexiform neurofibromas. The company has raised USD 75.00 mn in total funding, including a USD 224.30 mn PIPE round completed on September 12, 2019 with Boxer Capital and Deerfield Management. Saqib Islam is CEO. In 2021 the company reported zero revenue and USD -172.98 mn EBITDA.

3Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in